Elite Pharmaceuticals (OTCQB: ELTP), a specialty pharmaceutical company focused on niche generic products, has scheduled its Fiscal Year 2025 financial results release for June 30, 2025, followed by a conference call on July 1, 2025, at 11:30 AM EDT. Management will discuss financial and operating results while providing a business update. Shareholders can submit general questions by June 27 (5:00 PM EDT) and financial questions by June 30 (7:00 PM EDT) to [email protected]. The call can be accessed via domestic (1-800-346-7359) or international (1-973-528-0008) dial-in numbers using conference number 98840, with audio replay available at elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB: ELTP), un'azienda farmaceutica specializzata in prodotti generici di nicchia, ha programmato la pubblicazione dei risultati finanziari per l'anno fiscale 2025 il 30 giugno 2025, seguita da una conference call il 1掳 luglio 2025 alle 11:30 EDT. Il management discuter脿 i risultati finanziari e operativi fornendo anche un aggiornamento sull'andamento aziendale. Gli azionisti possono inviare domande generali entro il 27 giugno (ore 17:00 EDT) e domande finanziarie entro il 30 giugno (ore 19:00 EDT) all'indirizzo [email protected]. La chiamata 猫 accessibile tramite i numeri nazionali (1-800-346-7359) o internazionali (1-973-528-0008) utilizzando il numero di conferenza 98840, con la possibilit脿 di ascoltare la registrazione audio su elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB: ELTP), una empresa farmac茅utica especializada en productos gen茅ricos de nicho, ha programado la publicaci贸n de sus resultados financieros del a帽o fiscal 2025 para el 30 de junio de 2025, seguida de una conferencia telef贸nica el 1 de julio de 2025 a las 11:30 AM EDT. La direcci贸n discutir谩 los resultados financieros y operativos, adem谩s de proporcionar una actualizaci贸n del negocio. Los accionistas pueden enviar preguntas generales hasta el 27 de junio (5:00 PM EDT) y preguntas financieras hasta el 30 de junio (7:00 PM EDT) al correo [email protected]. La llamada se puede acceder mediante los n煤meros nacionales (1-800-346-7359) o internacionales (1-973-528-0008) usando el n煤mero de conferencia 98840, con reproducci贸n de audio disponible en elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB : ELTP), une soci茅t茅 pharmaceutique sp茅cialis茅e dans les produits g茅n茅riques de niche, a programm茅 la publication de ses r茅sultats financiers pour l'exercice 2025 le 30 juin 2025, suivie d'une conf茅rence t茅l茅phonique le 1er juillet 2025 脿 11h30 EDT. La direction discutera des r茅sultats financiers et op茅rationnels tout en fournissant une mise 脿 jour sur l'activit茅. Les actionnaires peuvent soumettre des questions g茅n茅rales jusqu'au 27 juin (17h00 EDT) et des questions financi猫res jusqu'au 30 juin (19h00 EDT) 脿 l'adresse [email protected]. L'appel est accessible via les num茅ros d'appel nationaux (1-800-346-7359) ou internationaux (1-973-528-0008) en utilisant le num茅ro de conf茅rence 98840, avec une rediffusion audio disponible sur elite.irpass.com/events_presentations.
Elite Pharmaceuticals (OTCQB: ELTP), ein auf Nischen-Generika spezialisiertes Pharmaunternehmen, hat die Ver枚ffentlichung der Finanzergebnisse f眉r das Gesch盲ftsjahr 2025 f眉r den 30. Juni 2025 geplant, gefolgt von einer Telefonkonferenz am 1. Juli 2025 um 11:30 Uhr EDT. Das Management wird die finanziellen und operativen Ergebnisse besprechen und ein Unternehmensupdate geben. Aktion盲re k枚nnen allgemeine Fragen bis zum 27. Juni (17:00 Uhr EDT) und finanzielle Fragen bis zum 30. Juni (19:00 Uhr EDT) an [email protected] senden. Der Anruf ist 眉ber nationale (1-800-346-7359) oder internationale (1-973-528-0008) Einwahlnummern mit der Konferenznummer 98840 zug盲nglich, eine Audio-Wiedergabe ist unter elite.irpass.com/events_presentations verf眉gbar.
Positive
None.
Negative
None.
Financials for Fiscal Year 2025 Ended March 31, 2025 will be released on Monday, June 30, 2025
Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2025 year-end financial results on Monday, June 30, 2025. Elite's management will host a live conference call on Tuesday, July 1st, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. Stockholders should submit questions to the company before the call.
[email protected] General questions by 5:00 PM EDT on Friday, June 27, 2025 Financial questions by 7:00 PM EDT on Monday, June 30, 2025
Audio Replay:
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit .
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
To view the source version of this press release, please visit
FAQ
When will Elite Pharmaceuticals (ELTP) release its FY 2025 financial results?
Elite Pharmaceuticals will release its FY 2025 financial results on Monday, June 30, 2025.
What time is Elite Pharmaceuticals' (ELTP) earnings conference call on July 1, 2025?
The conference call is scheduled for 11:30 AM EDT on July 1, 2025.
How can shareholders submit questions for Elite Pharmaceuticals' (ELTP) earnings call?
Shareholders can email questions to [email protected] - general questions by June 27, 2025 (5:00 PM EDT) and financial questions by June 30, 2025 (7:00 PM EDT).
What are the dial-in numbers for Elite Pharmaceuticals' (ELTP) conference call?
The dial-in numbers are 1-800-346-7359 (domestic) and 1-973-528-0008 (international), with conference number 98840.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
